A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
Abroad (travel likely)RecruitingEARLY_PHASE1
Conditions
Acute Lymphoblastic Leukemia · Non-hodgkin Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou, Zhejiang, China
Contact: Principal Investigator (He Huang, MD)